The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
 
Ian E. Krop
Employment - Freeline Therapeutics (I); PureTech (I)
Leadership - Freeline Therapeutics (I); PureTech (I)
Stock and Other Ownership Interests - Freeline Therapeutics (I); PureTech (I)
Honoraria - AstraZeneca; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Macrogenics; Merck; Novartis; Seagen
Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group ; Japanese Breast Cancer Society
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa-Kirin; Lilly Japan; Novartis; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Toru Mukohara
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Novartis; Pfizer; Taiho Oncology
Research Funding - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sysmex
 
Shunji Takahashi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Takahiro Nakayama
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical
 
Kenichi Inoue
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Tatsuya Toyama
Consulting or Advisory Role - Daiichi Sankyo; Pfizer
Speakers' Bureau - AstraZeneca; Chugai Pharma; Nippon Kayaku; Novartis; Pfizer; Takeda
 
Yutaka Yamamoto
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer
Research Funding - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; MSD Oncology; Nippon Kayaku; Pfizer; Taiho Pharmaceutical; Takeda
Other Relationship - Japan Breast Cancer Research Group; Japanese Breast Cancer Society
 
Damien Mikael Hansra
Employment - Cancer Treament Centers of America; Hansra Health Corporation
 
Masato Takahashi
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly; Pfizer
Research Funding - Eisai (Inst); Kyowa Hakko Kirin (Inst); Nippon Kayaku (Inst); Taiho Pharmaceutical (Inst)
 
Akihiko Osaki
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Nippon Kayaku; Novartis
Research Funding - AstraZeneca; Chugai Pharma; Covance; Daiichi Sankyo; Eisai; Kyowa Kirin; MSD; Taiho Pharmaceutical
 
Kumiko Koyama
Employment - Daiichi Sankyo Co., Ltd.
 
Tatsuya Inoue
Employment - Daiichi Sankyo RD Novare
 
Takatoshi Yonekura
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Joseph Mostillo
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Shoichi Ohwada
Employment - Daiichi Sankyo
 
Yoshimi Tanaka
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
David W. Sternberg
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)